Plain-English translation of NCT05546827 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating two rare types of melanoma—one that starts in the sinuses and one that starts in the rectal area. The study combines immunotherapy (which helps your body's immune system fight cancer) with radiation therapy, given before surgery to remove the tumor. Researchers want to see whether this combination approach helps shrink tumors and improves how well surgery works.
These types of melanoma are extremely rare and difficult to treat, and surgery alone doesn't always work well enough. This trial is testing whether giving the medication and radiation first can make tumors smaller and easier to remove, and potentially improve long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would first receive immunotherapy injections or infusions to help your immune system fight the cancer. After that, you would undergo radiation therapy—either 5 sessions or 20 sessions depending on your cancer type and how it responds. Finally, you would have surgery to remove any remaining tumor. Throughout this process, you'll have regular doctor visits, imaging scans, and blood tests to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~40 participants
Started
October 2022
Primary completion
July 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Devarati Mitra, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.